Compare EVTV & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTV | CMMB |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 9.1M |
| IPO Year | 2014 | 2023 |
| Metric | EVTV | CMMB |
|---|---|---|
| Price | $1.31 | $1.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 803.5K | 74.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $1,870,060.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $0.87 |
| 52 Week High | $5.07 | $3.86 |
| Indicator | EVTV | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 56.77 |
| Support Level | $1.30 | $1.48 |
| Resistance Level | $1.34 | $2.80 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | -0.07 | 0.05 |
| Stochastic Oscillator | 9.53 | 78.46 |
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.